Article Details

Daiichi Sankyo and Merck dose first subject in ovarian cancer trial

Retrieved on: 2024-04-04 11:18:03

Tags for this article:

Click the tags to see associated articles and topics

Daiichi Sankyo and Merck dose first subject in ovarian cancer trial. View article details on hiswai:

Excerpt

AstraZeneca Plc · View all. The multicentre, randomised, open-label trial will assess the efficacy and safety of the ADC in approximately 650 ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up